EDUCATION

Medical School

  • University of Torino Medical School , 1993 , Torino , Italy

Residency

Anatomic Pathology
  • University of Torino Medical School , 1997 , Torino , Italy

Fellowship

Hematology and Molecular Pathology
  • New York University Medical Center , 2001 , New York , NY

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Proc Natl Acad Sci U S A. 2021 Feb 09; 118(6). View abstract
  2. Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell Stem Cell. 2021 Jan 25. View abstract
  3. High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells. Cancers (Basel). 2020 Oct 13; 12(10). View abstract
  4. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. Blood. 2020 Oct 01; 136(14):1657-1669. View abstract
  5. Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. Lung Cancer. 2020 08; 146:366-369. View abstract
  6. CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation. Cell Rep. 2019 07 30; 28(5):1307-1322.e8. View abstract
  7. RHO Family GTPases in the Biology of Lymphoma. Cells. 2019 06 26; 8(7). View abstract
  8. Comment on "ALK is a therapeutic target for lethal sepsis". Sci Transl Med. 2018 12 12; 10(471). View abstract
  9. Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nat Med. 2019 01; 25(1):130-140. View abstract
  10. Parp3 promotes long-range end joining in murine cells. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):10076-10081. View abstract
  11. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers (Basel). 2018 Feb 28; 10(3). View abstract
  12. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018 02 08; 172(4):857-868.e15. View abstract
  13. The CRISPR/Cas9 System as a Tool to Engineer Chromosomal Translocation In Vivo. Adv Exp Med Biol. 2018; 1044:39-48. View abstract
  14. Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2a Scaffolding Function. Cancer Cell. 2017 10 09; 32(4):444-459.e7. View abstract
  15. Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget. 2017 Nov 03; 8(54):92265-92274. View abstract
  16. Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. Clin Immunol. 2017 10; 183:142-144. View abstract
  17. A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature. 2017 08 10; 548(7666):239-243. View abstract
  18. Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. Vaccines (Basel). 2017 Aug 01; 5(3). View abstract
  19. Developmentally-faithful and effective human erythropoiesis in immunodeficient and Kit mutant mice. Am J Hematol. 2017 Sep; 92(9):E513-E519. View abstract
  20. Primary Cutaneous B-Cell Lymphoblastic Lymphoma Arising from a Long-Standing Lesion in a Child and Review of the Literature. Pediatr Dermatol. 2017 Jul; 34(4):e182-e186. View abstract
  21. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. Oncotarget. 2017 Mar 21; 8(12):18680-18698. View abstract
  22. Phosphatidylinositol 3-kinase d blockade increases genomic instability in B cells. Nature. 2017 02 23; 542(7642):489-493. View abstract
  23. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget. 2017 Jan 10; 8(2):3274-3288. View abstract
  24. Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms. Proc Natl Acad Sci U S A. 2017 01 17; 114(3):E327-E336. View abstract
  25. Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. Cancer Res. 2016 10 15; 76(20):6095-6106. View abstract
  26. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. Oncotarget. 2016 May 31; 7(22):33316-30. View abstract
  27. Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. Elife. 2016 Mar 17; 5. View abstract
  28. Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nat Commun. 2016 Mar 09; 7:10934. View abstract
  29. Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016 Feb; 21(114):125-33. View abstract
  30. Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. Blood. 2016 Mar 10; 127(10):1297-306. View abstract
  31. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene. 2016 07 21; 35(29):3854-3865. View abstract
  32. Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunol Res. 2015 Dec; 3(12):1333-1343. View abstract
  33. The anaplastic lymphoma kinase as an oncogene in solid tumors. Front Biosci (Schol Ed). 2015 Jun 01; 7:269-82. View abstract
  34. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015 Apr 09; 161(2):319-32. View abstract
  35. A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment. Nanomedicine. 2015 Apr; 11(3):741-50. View abstract
  36. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 2014 Nov 20; 9(4):1219-27. View abstract
  37. Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. Blood Cancer J. 2014 Oct 10; 4:e249. View abstract
  38. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res. 2014 Nov 01; 74(21):5978-88. View abstract
  39. STAT3ß controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. Am J Cancer Res. 2014; 4(5):484-94. View abstract
  40. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. Cancer Res. 2014 Nov 01; 74(21):6094-106. View abstract
  41. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study. Lung Cancer. 2014 Aug; 85(2):191-6. View abstract
  42. IgH class switching exploits a general property of two DNA breaks to be joined in cis over long chromosomal distances. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):2644-9. View abstract
  43. FuseFISH: robust detection of transcribed gene fusions in single cells. Cell Rep. 2014 Jan 16; 6(1):18-23. View abstract
  44. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J Hematol Oncol. 2013 Sep 06; 6:67. View abstract
  45. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. Neoplasia. 2013 May; 15(5):511-22. View abstract
  46. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis. 2013 Apr 08; 2:e43. View abstract
  47. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat Methods. 2013 Apr; 10(4):361-5. View abstract
  48. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. EMBO Mol Med. 2013 Apr; 5(4):572-90. View abstract
  49. Tissue flow cytometry immunophenotyping in the diagnosis and classification of non-Hodgkin's lymphomas: a retrospective evaluation of 1,792 cases. Cytometry B Clin Cytom. 2013 Mar; 84(2):82-95. View abstract
  50. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology. 2013 May; 144(5):1098-106. View abstract
  51. Translocations in normal B cells and cancers: insights from new technical approaches. Adv Immunol. 2013; 117:39-71. View abstract
  52. The battle against ALK resistance: successes and setbacks. Expert Opin Investig Drugs. 2012 Dec; 21(12):1751-4. View abstract
  53. Calming down T cell acute leukemia. Cancer Cell. 2012 Apr 17; 21(4):449-50. View abstract
  54. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012 Jan 05; 481(7379):90-3. View abstract
  55. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell. 2011 Sep 30; 147(1):107-19. View abstract
  56. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther. 2011 Dec; 19(12):2201-12. View abstract
  57. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma. 2011 Sep; 52(9):1742-50. View abstract
  58. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood. 2011 Jun 16; 117(24):6617-26. View abstract
  59. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther. 2011 Jun; 19(6):1131-40. View abstract
  60. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu Rev Immunol. 2011; 29:319-50. View abstract
  61. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS One. 2010 Oct 01; 5(10). View abstract
  62. Expression of IFN?R2 mutated in a dileucine internalization motif reinstates IFN? signaling and apoptosis in human T lymphocytes. Immunol Lett. 2010 Nov 30; 134(1):17-25. View abstract
  63. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem. 2010 Aug 20; 285(34):26441-50. View abstract
  64. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Mol Carcinog. 2010 Feb; 49(2):114-20. View abstract
  65. MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Dev Cell. 2010 Jan 19; 18(1):77-89. View abstract
  66. The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. Adv Immunol. 2010; 106:93-133. View abstract
  67. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol. 2009 Dec; 27(4):161-70. View abstract
  68. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009 Nov 15; 69(22):8611-9. View abstract
  69. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother. 2009 Nov-Dec; 32(9):920-31. View abstract
  70. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer. 2009 Aug 01; 125(3):639-48. View abstract
  71. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia. 2009 Nov; 23(11):2102-8. View abstract
  72. Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin. Eur J Immunol. 2009 Apr; 39(4):1136-46. View abstract
  73. Anaplastic lymphoma kinase: an oncogene for tumor vaccination. J Mol Med (Berl). 2009 Jul; 87(7):669-77. View abstract
  74. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008 Nov 01; 68(21):8899-907. View abstract
  75. Heat shock protein expression in diabetic nephropathy. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1817-24. View abstract
  76. The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood. 2009 Mar 19; 113(12):2776-90. View abstract
  77. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008 Jun; 14(6):676-80. View abstract
  78. Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. Front Biosci. 2008 May 01; 13:6501-14. View abstract
  79. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res. 2008 Apr 01; 14(7):2220-6. View abstract
  80. High energy shock waves (HESW) increase paclitaxel efficacy in a syngeneic model of breast cancer. Technol Cancer Res Treat. 2008 Apr; 7(2):117-24. View abstract
  81. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008 Jan; 8(1):11-23. View abstract
  82. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res. 2007 Oct; 6(10):4025-31. View abstract
  83. Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma. Proc Natl Acad Sci U S A. 2007 Sep 04; 104(36):14354-9. View abstract
  84. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol. 2007 Sep; 149(3):504-12. View abstract
  85. The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. J Cell Sci. 2007 Jun 01; 120(Pt 11):1859-67. View abstract
  86. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007 May 01; 67(9):4278-86. View abstract
  87. Conditional activation of MET in differentiated skeletal muscle induces atrophy. J Biol Chem. 2007 Mar 02; 282(9):6812-22. View abstract
  88. In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood. 2007 Mar 15; 109(6):2496-504. View abstract
  89. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006 Dec; 116(12):3171-82. View abstract
  90. Incestuous paternity detected by STR-typing of chorionic villi isolated from archival formalin-fixed paraffin-embedded abortion material using laser microdissection. J Forensic Sci. 2006 Jan; 51(1):90-2. View abstract
  91. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. . 2005 Sep; 4(9):1131-3. View abstract
  92. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood. 2006 Jan 15; 107(2):689-97. View abstract
  93. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005 Dec 01; 106(12):3907-16. View abstract
  94. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. Am J Clin Pathol. 2005 Aug; 124(2):182-90. View abstract
  95. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005 Jun; 11(6):623-9. View abstract
  96. RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. Cancer Gene Ther. 2005 May; 12(5):456-63. View abstract
  97. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol. 2004 Apr; 5(4):401-9. View abstract
  98. Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei. Virchows Arch. 2004 Apr; 444(4):350-5. View abstract
  99. Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J Biol Chem. 2004 Feb 06; 279(6):4136-43. View abstract
  100. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia. 2003 Nov; 17(11):2238-40. View abstract
  101. Role of CD30 in the maturation of thymocytes and in the pathogenesis of autoimmune diseases. Pathologica. 2003 Oct; 95(5):229-30. View abstract
  102. Expression of the CD31 antigen in normal B-cells and non Hodgkin's lymphomas. J Biol Regul Homeost Agents. 2003 Oct-Dec; 17(4):308-15. View abstract
  103. Estrogen receptor alpha is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor-associated lymphoid infiltrates. Am J Pathol. 2003 Oct; 163(4):1313-20. View abstract
  104. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol Cell Biol. 2002 Dec; 22(23):8375-87. View abstract
  105. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003 Mar 01; 101(5):1919-27. View abstract
  106. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol. 2002 Apr; 160(4):1457-66. View abstract
  107. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002 Feb 07; 21(7):1038-47. View abstract
  108. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2515-20. View abstract
  109. Induction of germinal centers by MMTV encoded superantigen on B cells. Dev Immunol. 2001; 8(3-4):201-11. View abstract
  110. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001; 3(2):91-4. View abstract
  111. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. Br J Haematol. 2000 Oct; 111(1):263-71. View abstract
  112. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem. 2000 Sep 01; 275(35):27110-6. View abstract
  113. Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa). Oncogene. 2000 May 25; 19(23):2767-73. View abstract
  114. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000 Jan 15; 95(2):619-26. View abstract
  115. Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. Am J Pathol. 1999 Aug; 155(2):355-63. View abstract
  116. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999 Jul 01; 163(1):194-205. View abstract
  117. CD30 in normal and neoplastic cells. Clin Immunol. 1999 Feb; 90(2):157-64. View abstract
  118. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. Am J Hematol. 1997 Dec; 56(4):206-13. View abstract
  119. Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL). Eur J Haematol. 1997 Sep; 59(3):148-54. View abstract
  120. Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with increased serum level of CA-125. Gynecol Oncol. 1997 Aug; 66(2):320-3. View abstract
  121. p53 expression and proliferative activity predict survival in non-invasive thymomas. Int J Cancer. 1996 Jun 21; 69(3):180-3. View abstract
  122. Long-term survival of thymoma patients by histologic pattern and proliferative activity. Am J Surg Pathol. 1995 Aug; 19(8):918-26. View abstract
  123. Identification of the same HRAS1 mutation in a primary minimally invasive follicular carcinoma of the thyroid gland and its bone metastasis developed 15 years later. Diagn Mol Pathol. 1995 Mar; 4(1):73-4. View abstract
  124. Argyrophilic nucleolar organizer region counts predict survival in thymoma. Cancer. 1994 Sep 01; 74(5):1568-74. View abstract